Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 16/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981322 | 0.85 | PPARD (0.43) | ALDH1A1MRGPRX4RXRARXRBRXRG | |
| SCHEMBL29088121 | 0.82 | MRGPRX4 (0.59) | MRGPRX4 | |
| SCHEMBL3985328 | 0.80 | IGF1R (0.39) | — | |
| SCHEMBL5613856 | 0.78 | PPARG (0.36) | KDM4EPPARDABCB1 | |
| SCHEMBL30427926 | 0.76 | MRGPRX4 (0.72) | MRGPRX4 | |
| SCHEMBL5389326 | 0.76 | MRGPRX4 (0.60) | MRGPRX4RXRARXRBRXRG | |
| SCHEMBL3982211 | 0.75 | PPARD (0.37) | KDM4EPPARD | |
| SCHEMBL3982215 | 0.75 | PPARD (0.37) | KDM4EPPARD | |
| SCHEMBL17050818 | 0.75 | MRGPRX4 (0.60) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3986776 | 0.74 | MRGPRX4 (0.57) | MRGPRX4RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | NR1H3, NR1H2, NR1I2 | KDM4E 2851/4885ALDH1A1 2395/4885CYP1A2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.